These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7077401)

  • 1. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: concise communication.
    Ramacciotti C; Pretorius HT; Line BR; Goldman JM; Robbins J
    J Nucl Med; 1982 Jun; 23(6):483-9. PubMed ID: 7077401
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the effectiveness between a single low dose and fractionated doses of radioiodine in ablation of post-operative thyroid remnants.
    Hung GU; Tu ST; Wu IS; Yang KT
    Jpn J Clin Oncol; 2004 Aug; 34(8):469-71. PubMed ID: 15371465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
    Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
    Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
    Bal C; Padhy AK; Jana S; Pant GS; Basu AK
    Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.
    Mallick U; Harmer C; Hackshaw A
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):325-6. PubMed ID: 18474322
    [No Abstract]   [Full Text] [Related]  

  • 6. [Radioactive iodine in the treatment of thyroid carcinoma].
    Pendić S; Tasić S
    Srp Arh Celok Lek; 1980 Oct; 108(10):1021-9. PubMed ID: 7292160
    [No Abstract]   [Full Text] [Related]  

  • 7. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
    Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
    Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.
    Zidan J; Hefer E; Iosilevski G; Drumea K; Stein ME; Kuten A; Israel O
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1330-6. PubMed ID: 15275717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the efficacy of iodine-131 for thyroid ablation.
    Comtois R; Thériault C; Del Vecchio P
    J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
    Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
    J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid cancer guidelines--what's new?
    Gerrard G; Gill V
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):264-6. PubMed ID: 18343311
    [No Abstract]   [Full Text] [Related]  

  • 13. [Guidelines and results in the treatment of thyroid cancer].
    Ortíz Berrocal J; Sopena Monforte R; Carril Carril JM; Ramos Sánz J; Martínez R; Chamorro Romero JL
    Rev Clin Esp; 1977 Jun; 145(5):361-8. PubMed ID: 877349
    [No Abstract]   [Full Text] [Related]  

  • 14. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure.
    Driedger AA; Quirk S; McDonald TJ; Ledger S; Gray D; Wall W; Yoo J
    Clin Nucl Med; 2006 Aug; 31(8):454-7. PubMed ID: 16855429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiated thyroid cancer: lobectomy and radioiodine, a treatment suitable for all cases?
    Allan E; Owens SE; Waller ML
    Nucl Med Commun; 1999 Nov; 20(11):983-9. PubMed ID: 10572907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablation dose of iodine-131 for postoperative remnant.
    Park HM
    J Nucl Med; 1991 Aug; 32(8):1640-1. PubMed ID: 1869994
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy.
    Bal CS; Kumar A; Chandra P; Dwivedi SN; Pant GS
    Acta Oncol; 2006; 45(8):1067-72. PubMed ID: 17118841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical study of 312 cases with matastatic differentiated thyroid cancer treated with large doses of 131I.
    Zhu RS; Yu YL; Lu HK; Luo QY; Chen LB
    Chin Med J (Engl); 2005 Mar; 118(5):425-8. PubMed ID: 15780216
    [No Abstract]   [Full Text] [Related]  

  • 19. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma.
    Salvatori M; Raffaelli M; Castaldi P; Treglia G; Rufini V; Perotti G; Lombardi CP; Rubello D; Ardito G; Bellantone R
    Eur J Surg Oncol; 2007 Jun; 33(5):648-54. PubMed ID: 17433606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.